Pfizer is preparing for a consumer market for obesity drugs on par with the booming business it saw after it launched ...

Pfizer $4.9 billion cash acquisition of Metsera, a clinical-stage biotech focused on next-generation obesity drugs, is more than another high-profile deal in pharma’s dealmaking spree. It signals a ...

Nov 5 (Reuters) - Pfizer (PFE.N), opens new tab is preparing to sweeten its offer again for Metsera (MTSR.O), opens new tab, the Wall Street Journal reported on Wednesday, citing people familiar with ...

Pfizer Inc. provided early 2025 and 2026 guidance, projecting flat-to-declining revenues and EPS, highlighting persistent growth and profitability challenges. Pfizer faces major patent expiries, ...